Beltroni AI Agents for Protein Binder Design: From In-Silico Discovery to Wet Lab Handoff
In the rapidly evolving frontier of health science, protein binder design has stood as a complex, time-intensive bottleneck. Today, we are proud to introduce Nikola, powered by our On-premises Bio-Servers — our most advanced Research AI Agent, custom-engineered to accelerate rejuvenation protein binder design and breakthrough health discovery. No sequence data ever leaves your facility.
Bio-Server Discovery Campaigns
Campaigns run continuously and autonomously, not as one-off runs. At a 12-minute average per discovery run, a single Bio-Server converts a full day of uptime into:
At 9 ranked candidates per discovery run, that is 1,080 candidates a day and 7,560 a week from one server — every one of them a computational prediction queued for wet-lab confirmation, not a validated binder.
A discovery campaign running end to end in the Bio-Server. The interface, pose and fold confidences shown are prediction scores — as the panel itself notes, not binding measurements.
| Platform | Speed | What it covers | Deployment |
|---|---|---|---|
| Beltroni AI Bio-Server | ~12 min / 9 candidates (full pipeline, average) | All six phases in silico — target ID → design → fold → interface scoring → ADMET → lead report | On-premises |
Figures reflect production hardware, measured across all six in-silico phases — target identification through the exported lead report. Every value is a computational prediction, not a wet-lab measurement.
The Beltroni AI Bio-Server takes 9 binder candidates through the full in-silico pipeline in about 12 minutes on average, on our latest hardware at a fraction of cloud cost. No sequence data leaves the facility. To be unambiguous about what that means: every number Nikola produces is a prediction. The pipeline ranks candidates by predicted structure, predicted interface quality, and predicted ADMET properties — it does not measure binding. Nothing is confirmed as a binder until it is synthesized and assayed in a wet lab. What the platform buys a research team is a far better-ordered queue for that bench time, not a substitute for it.
Beltroni Bio-Server — Verified Targets by Category
The figures below come from campaigns our Bio-Servers run every day against a widening set of targets, not from a one-off benchmark. Each target is taken through the full six-phase pipeline again and again, and a category only appears here once enough runs have accumulated for its rate to mean something rather than describe a lucky batch. The table is therefore a snapshot of where validation currently stands — the counts grow and the rates move as campaigns continue.
| # | Category | Verified targets | Runs / Designs | Measured range | Median |
|---|---|---|---|---|---|
| count | count / count | % structural rate | % structural rate | ||
| 1 | Skin, ECM and Aesthetics | 12 | 78 / 933 | 35–91% | 68% |
| 2 | Oncology | 7 | 32 / 288 | 62–84% | 73% |
| 3 | Rejuvenation, Muscle and Lifespan | 6 | 37 / 443 | 40–89% | 79% |
| 4 | Inflammation and Immunology | 5 | 26 / 234 | 38–80% | 61% |
| 5 | Haematology | 4 | 18 / 162 | 51–82% | 79% |
| 6 | Anti-Infective | 2 | 10 / 90 | 67–80% | 74% |
| 6 | Metabolic and Body Composition | 2 | 10 / 90 | 62–76% | 69% |
Percentages are structural success rates — the share of designed candidates that independently refold into the shape they were designed for. They are not binding affinities, and no binding affinity is reported: no current computational method can reliably separate a real binder from a decoy without experimental testing.
Beltroni Bio-Server — Potential Applications
What this output can be used for, sorted honestly by how much our targets' capability catalogue actually backs each one — not by market size.
| Application | Fit | Why |
|---|---|---|
| Therapeutic candidates | Primary 38 of 38 Verified | The direct, intended use, and where nearly every catalogue entry sits: 38 Verified targets across 7 therapeutic areas, 35–91% structural range. |
| CAR / cell-therapy targeting domains | Real, evidenced 3 of 38 Verified | Mesothelin — Verified here against a VHH-defined epitope — plus Verified HER2 and EGFR ectodomains: three established CAR-T antigens. A de novo binder against a validated surface antigen is a plausible CAR-construct targeting domain, not only a standalone therapeutic. |
| Diagnostic / biosensor reagents | Real, evidenced 2 of 38 Verified | Dengue NS1 and SARS-CoV-2 spike RBD — both Verified here (80% / 67% structural, 97.2% / 90.0% interface) — are the same viral-antigen class most rapid diagnostic tests detect. |
| Affinity purification reagents | Possible, unproven 0 of 38 Verified | Chromatography ligands need different properties — regeneration-cycle robustness, generic rather than epitope-specific capture — than what this pipeline is built to optimize for. |
| Agricultural protective binders | Possible, unproven 0 of 38 Verified | Extrapolated from general antifungal / antibacterial target compatibility, not demonstrated. |
“Verified” is an in-silico status: structural and interface metrics that cleared the pipeline's gates. It is not wet-lab confirmation of binding.
What's Next
- Clinical & IND-filing workflows remain the customer's own regulated pathway, keeping Bio-Server focused on the computational discovery stage it does best.
AlphaFold vs Bio-Server
AlphaFold-class models are structure predictors, not the full pipeline. Where a “Yes” appears, they can substitute for that one phase — not for target identification, sequence design, developability screening, or the lead report around it. Beltroni Bio-Server is a full-pipeline protein design and drug discovery engine.
| Phase | Bio-Server | AlphaFold-class |
|---|---|---|
| 1 · Target ID Structure resolution, epitope, pathway | Yes | No |
| 2 · Sequence generation Backbone design + inverse folding | Yes | No |
| 3 · Self-consistency Refold designs as monomers | Yes | Yes |
| 4 · Interface scoring Fold binder against target | Yes | Yes |
| 5 · Developability Physicochemical properties | Yes | No |
| 6 · Lead report Interpretation | Yes | No |
Beltroni Bio-Server and Nikola use advanced AI models.
Augmenting Cellular Health Science
Protein-protein interactions carry the signaling that coordinates biological processes ranging from cellular regeneration to immune modulation, which makes an engineered binder a precise lever on that system. Design has long proceeded through iterative experimental cycles. Nikola complements this work by adding a layer of predictive optimization ahead of physical experimentation. By analyzing millions of molecular structures, Nikola maps predicted binding behavior, then surfaces and ranks promising therapeutic pathways for researcher review.
The Molecular Hallmarks of Aging: Targeted Interventions
The modern rejuvenation research field has, over roughly the last fifteen years, converged on a shared framework often called the hallmarks of aging: a relatively short list of distinct, interconnected failure modes that collectively produce what we experience as aging. Under this framework, each hallmark is a category of biological degradation, and each has an active research program devoted to developing therapeutic counter-measures.
Epigenetic Alterations
As cells age, they undergo progressive alterations in chromatin structure, including global DNA hypomethylation, promoter-specific hypermethylation, and histone modification shifts. These changes disrupt key gene expression programs—silencing protective rejuvenation pathways while leaving inflammatory pathways open. The research objective is epigenetic reprogramming: guiding DNA methylation patterns back toward more youthful configurations.
Cellular Senescence
Senescence represents a state of permanent cell cycle arrest triggered by cumulative genomic stress, telomere attrition, or oncogenic activation. Senescent cells remain metabolically active, secreting a noxious cocktail of pro-inflammatory cytokines, chemokines, and matrix metalloproteinases known as the Senescence-Associated Secretory Phenotype (SASP). SASP spreads senescence to adjacent healthy tissue and drives systemic chronic inflammation ("inflammaging"). The therapeutic mission is senolytics: targeted binders designed to selectively trigger apoptosis in senescent cells without harming healthy surrounding tissue.
Mitochondrial Dysfunction
Mitochondrial efficiency declines sharply with age, marked by reduced integrity of the electron transport chain, decreased ATP production, and an accumulation of somatic mitochondrial DNA (mtDNA) mutations. This metabolic decline leads to elevated reactive oxygen species (ROS) production, causing oxidative damage to cellular organelles and triggering chronic intracellular stress. Advanced binder discovery focuses on mitochondria-targeted binders (such as SS-31 analogues or cardiolipin stabilizers) that restore membrane potential, reduce ROS emissions, and upregulate PGC-1α to stimulate mitochondrial biogenesis.
Loss of Proteostasis
Proteostasis involves the coordinated network of ribosomes, chaperones (such as heat shock proteins), and degradation systems (autophagy-lysosome and ubiquitin-proteasome pathways) that ensure correct protein synthesis, folding, and clearance. In aging cells, this quality-control machinery decays, resulting in the intracellular accumulation of harmful misfolded proteins and aggregates. Rejuvenation research employs custom-engineered binders that activate chaperones or stimulate autophagy to restore cellular clearance mechanisms and prevent aggregate-induced damage.
Infrastructure: Beltroni AI Bio-Server
These dedicated hardware servers run the computational discovery pipelines on Beltroni premises, enabling structural folding simulations and predicted interface scoring without transmitting sequence data outside our private network security perimeter. This model keeps sequence data on hardware the customer controls, gives dedicated compute with no cloud round-trip latency, and dedicated AI accelerator compute power for continuous, high-throughput rejuvenation research.
Beltroni AI Bio-Server and Nikola assisting researchers and lab teams
AI System Guardrails & Infrastructure Security
In high-stakes research, an AI agent is only as valuable as it is trustworthy. We treat guardrails and infrastructure security not as features bolted on at the end, but as the foundation Nikola is built upon: proprietary data stays inside the organization's own network, outputs are constrained to scientifically valid space, and every inference is auditable end to end.
These guardrails are already in production, and they are continuously evolving. This is especially true at the target-selection stage—the most consequential decision point in the pipeline—where the safeguards governing which targets an agent may pursue remain an area of active refinement with our vetted research partners.
Constrained Generation
Outputs are bounded to scientifically valid space, with in-silico gates that reject unstable, non-viable, or likely off-target candidates before they reach a researcher, so that far less of what does reach them needs to be discarded by hand.
Data Sovereignty & Isolation
Proprietary sequences and model weights never leave the private security perimeter. Running on Beltroni premises removes third-party cloud exposure entirely, protecting intellectual property and satisfying the strictest compliance and IP-security requirements.
Auditability & Access Control
Every inference is logged, and every capability is gated by role-based access. Autonomous actions carry scope and rate limits, so the agent operates within clearly defined boundaries—producing reproducible, defensible records for regulatory review.
🔒 Nikola is available exclusively through partnership. Sign up below to begin the process, and our team will reach out to discuss access.
Rejuvenation Research AI Agents — Nikola
Are you a US-based rejuvenation health science group looking to revolutionize protein binder design? Connect with our team to apply for early access to the Nikola advanced research system.
Sign Up to BeginRefactoring Longevity — A Book by Beltroni AI's Founder
While the primary audience is software engineers navigating a career pivot, the translation layer holds up for a wider circle of readers too. Others who will get real value out of this book include:
- Business managers, leaders, and investors seeking a technical edge in rejuvenation
- Engineering managers and technical leads scoping out where their team's skills could transfer next
- Any professional with a programming background who's genuinely curious about lifespan and rejuvenation science
- Product managers and technical founders considering a move into biotech or health tech
- Self-taught builders and lifelong learners drawn to emerging, high-impact fields
Through this comparative lens, you will discover how AI-driven drug discovery tools are used like modern IDEs to write custom de novo small protein scripts — small molecular request payloads designed to hit specific public cellular endpoints (like the Adenosine A2A receptor) to trigger backend cleanup tasks. You will learn how biological Time-To-Live (TTL) prevents systemic network congestion, how autophagy acts as a native garbage collector, and how pioneers are building genetic “on/off switches” to run live disk-cleanup operations on human DNA.
Further Reading
Refactoring Longevity — chmod +x Biology
The Systems Engineer's Guide to Cellular Communication and De Novo Peptides. An educational, vendor-neutral introduction to the systems-engineering way of thinking about biological rejuvenation.
Read on Amazon →Currently available in the United States, Canada, Australia and United Kingdom, with more regions coming soon.